bullish

Resapp Health

ResApp’s Confirmatory Study Fails, Resulting in Pfizer’s Lower A$0.146 Offer

435 Views21 Jun 2022 19:28
The revised SID provides no obvious way for Pfizer to pull its offer. At the last close of A$0.125, the gross spread to the unconfirmed data offer price of A$0.146 is 16.8%.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Arun George
IPOs and Catalysts/Events
Global Equity Research Ltd
Information TechnologyEquitiesEquity Capital MarketsEvent-Driven
x